Ventricular fibrillation induced by ischemia-reperfusion is not prevented by the NPY Y2 receptor antagonist BIIE0246.

Abstract

Neuropeptide Y is released together with norepinephrine from sympathetic nerve terminals during conditions of increased sympathetic activity. Neuropeptide Y is known to inhibit vagal activity, and accordingly, it might increase the risk for ventricular fibrillation during myocardial ischemia-reperfusion, with concomitant sympathetic stimulation. Counteracting the inhibiting effect of neuropeptide Y by the specific neuropeptide Y2 antagonist, BIIE0246, we expected occurrence of ventricular fibrillation in association with repeated periods of myocardial ischemia-reperfusion to decrease. The midleft anterior descending coronary artery was repeatedly occluded in 16 open-chest pigs. Eight pigs received BIIE0246, and the controls received the vehicle only. Ventricular fibrillation developed in 2 animals of the control group, but in 4 pigs receiving BIIE0246. Occurrence of ventricular fibrillation and ventricular tachycardia did not differ significantly between the 2 groups, and in association with repeated periods of regional myocardial ischemia, did not decline in pigs treated by the specific neuropeptide Y2-receptor antagonist BIIE0246.

• Authors: Arnfinn Ilebekk, Morten Eriksen, Knut Sevre, Trude Aspelin, Jan-Arne Björkman, Torstein Lyberg, Margareta Nordlander
• Journal: Journal of cardiovascular pharmacology and therapeutics (J Cardiovasc Pharmacol Ther) Vol. 11 Issue 3 Pg. 177-83 (Sep 2006) ISSN: 1074-2484 [Print] United States
• PMID: 17056830 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Benzazepines
• Biomarkers
• Receptors, Neuropeptide Y
• neuropeptide Y2 receptor
• Carbon Dioxide
• Arginine
• BIIE 0246
• Potassium
• Oxygen

Topics

• Animals
• Arginine (analogs & derivatives, blood, pharmacology)
• Benzazepines (blood, pharmacology)
• Biomarkers (blood)
• Blood Pressure (drug effects)
• Body Temperature (drug effects)
• Carbon Dioxide (analysis, blood)
• Cardiac Output (drug effects)
• Coronary Circulation (drug effects)
• Coronary Stenosis (complications)
• Disease Models, Animal
• Female
• Heart Rate (drug effects)
• Hematocrit
• Male
• Myocardial Reperfusion (adverse effects)
• Myocardial Reperfusion Injury (etiology, prevention & control)
• Oxygen (analysis, blood)
• Potassium (blood)
• Receptors, Neuropeptide Y (antagonists & inhibitors, blood)
• Swine
• Tachycardia, Ventricular (etiology, physiopathology, prevention & control)
• Ventricular Fibrillation (etiology, physiopathology, prevention & control)